The experimental drug transforming weight loss, retatrutide [USA TODAY]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: USA TODAY
AI Overview Full Summary Retatrutide is an experimental injectable drug from Eli?Lilly that acts as a triple-agonist on GLP-1, GIP and glucagon receptors, showing greater weight-loss results than earlier GLP-1 drugs in early trials. The medication is in large Phase?3 studies but has not yet received FDA approval, and experts stress that lasting weight control still requires diet, exercise and lifestyle changes. By now, very few people haven't heard of Ozempic . Originally developed to treat type 2 diabetes by mimicking hormones that regulate blood sugar, the medication quickly became better known for its powerful impact on weight loss due to the way the same mimicking hormones affect appetite. But while Ozempic is arguably the most recognizable drug in its class, it isn't the only medication approved for weight management. Others include Wegovy and Saxenda, while newer drugs like tirzepatide (sold as Mounjaro and Zepbound) work through related hormonal pathways. Now, addition
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US [Yahoo! Finance]Yahoo! Finance
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPR Newswire
- Franklin Rising Dividends Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's CEO Says This Could Be a Game Changer for Its Business [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website